Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Phenogen Sciences, Inc. today announced the availability of BREVAGenplus, an easy-to-use predictive risk test for the millions of women at risk of developing sporadic, or non-hereditary, breast cancer. The test is an enhancement of the company’s first generation product, BREVAGen®. BREVAGenplus assesses both clinical risk factors and genetic markers known to be associated with sporadic, or non-hereditary, breast cancer to determine a woman’s five-year and lifetime risk of developing the disease. The test is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans for Caucasian, Hispanic and African-American women, age 35 years or above, who have not had breast cancer, lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS), and have one or more risk factors for developing breast cancer.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7337351-phenogen-sciences-introduces-brevagenplus-breast-cancer-risk-assessment-test/
To help officially launch Prostate Cancer Awareness Month, the Prostate Cancer Foundation (PCF) has released a new public service announcement featuring Emmy® Award-winning sports anchor and prostate cancer survivor, Brian Custer. This survivor story aims to raise awareness about the importance of prostate cancer screening among African-American men by delivering a simple message: Man Up and Get Checked.
“As men, we have this ego…we think we’re too macho to go to the doctor and undergo this type of check-up,” said Custer, who hosts Showtime Championship Boxing. “But the truth is: If you don’t get checked, you’re cheating your family out of having a husband or father around. And you’re cheating yourself out of life. I hope when people hear my story, they’re motivated to take action by saying: ‘I’m going to get checked, I’m going to make sure my dad or husband gets checked, too.’”
To view the multimedia release go to:
http://www.multivu.com/players/English/7598151-prostate-cancer-foundation-brian-custer/
Significant advances toward cures for blood cancer patients, many of which were funded by The Leukemia & Lymphoma Society (LLS) over the past 65 years, are among the dramatic highlights featured in Ken Burns presents CANCER: THE EMPEROR OF ALL MALADIES, a film by Barak Goodman, to air on PBS stations nationwide from March 30-April 1. The documentary series is based on the Pulitzer Prize-winning book by Siddhartha Mukherjee, MD, The Emperor of All Maladies: A Biography of Cancer.
LLS has been a driving force behind treatment breakthroughs for patients with blood cancers, including leukemia, lymphoma and myeloma. As the world’s largest voluntary health agency dedicated to finding cures for blood cancer patients, LLS has invested more than $1billion in research to advance lifesaving treatments and cures.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7409151-lls-cancer-research-pbs-series/
If diagnosed early enough 90% of melanoma cases can be treated effectively. An exclusive study carried out by Ipsos for La Roche-Posay in 23 countries across all continents looks into the different attitudes to the sun and general knowledge of the risks associated with exposure. A massive 88% of those questioned are aware of the risks of developing skin cancer when exposed without protection to the sun. However, just 1 in 2 of those questioned have ever consulted a dermatologist for a mole screening and 1 in 4 of them have never even checked their own moles on their body.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7438251-la-roche-posay-become-skin-checker/
St. Jude Children’s Research Hospital®, uno de los principales centros de investigación y tratamiento del cáncer pediátrico se unió a Univision Radio, la mayor difusora de radio Hispana en los Estados Unidos, para realizar su evento radial anual Promesa y Esperanza®. Los radioyentes alrededor del país sintonizaron su estación favorita de Univision Radio el 7 y 8 de febrero y recaudaron más de $5.3 millones en efectivo y promesas monetarias. Los fondos recaudados ayudarán a cubrir los gastos de investigación y tratamiento del cáncer pediátrico y otras enfermedades terminales en los Estados Unidos, Puerto Rico y alrededor del mundo.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58260-st-jude-childrens-research-hospital-univision-radio-promesa-y-esperanza
“You have cancer.” Those three words are among the most dreaded and powerful a person can hear. In the case of Tony Harnell, the diagnosis of thyroid cancer was doubly frightening.
A vocalist/songwriter with a four-octave range, Harnell had toured in the U.S. with likes of Stryper, Twisted Sister and Great White and appeared on stages worldwide, entertaining legions of fans as lead singer with hard-rock band TNT.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62578-american-college-endocrinology-tony-harnell-advocate-thyroid-cancer-aware
The Prostate Cancer Foundation (PCF) and Major League Baseball (MLB) are once again teaming up to hit home runs for prostate cancer research and encourage fans to “Keep Dad in the Game” as part of the yearly celebration of Father’s Day and annual Home Run Challenge.
This year Joe Torre, MLB’s Chief Baseball Officer, Hall of Famer and prostate cancer survivor, encourages baseball fans everywhere to support PCF’s efforts to end prostate cancer by delivering an important public service announcement, “to step up to the plate, help save lives and get one step closer to finding a cure.”
“Joe has been a great partner in our progress toward improved treatment outcomes and an eventual cure,” said PCF Founder and Chairman Mike Milken. “His work as well as those by MLB and all 30 Clubs has helped us raise more than $45 million for research programs that are saving thousands of lives.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7729251-pcf-and-mlb-prostate-home-run-challenge/
Nucletron, an Elekta company, and the world leader in brachytherapy, has launched Esteya®, a new approach for treating patients with skin cancer.
Over the last 30 years, more people were diagnosed with skin cancer worldwide than all other cancers combined, making it the most common type of cancer1. This represents a challenge for health care providers in the years to come. With a cure rate of more than 95 percent2, electronic brachytherapy offers a refined treatment modality with excellent cosmesis.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62823-elekta-nucletron-esteya-electronic-brachytherapy-treating-skin-cancer
Imagine being diagnosed with one of the most rare and aggressive forms of breast cancer, given a five percent chance to live and told having children will never be an option. Southern California local Kommah McDowell was told just that— and then she went to City of Hope.
It is estimated that almost 40 percent of men and women in the U.S. will be diagnosed with cancer sometime during their lifetime. Kommah, who was diagnosed at age 29, now has her health and her son, thanks to discoveries made at City of Hope, where scientists and doctors turn laboratory breakthroughs into treatments that defeat cancer.
Today, the nonprofit research and comprehensive cancer center near Los Angeles is rolling out a new initiative that builds on its legacy of discovery to let people know that City of Hope not only offers a uniquely patient-centric, integrated approach to care, but also with the help of donors and volunteers, it is pursuing research that will change the future of medicine.
To view the multimedia release go to:
http://www.multivu.com/players/English/7665051-city-of-hope-miracle-science-soul-campaign/
In recognition of Men’s Health Awareness Month and the start of summer, the American Academy of Dermatology (Academy) has released findings from a new survey, which found that more than 90% of American men know something about skin cancer, but only six in 10 (61%) know how to detect signs on their skin, and even fewer actually visit a doctor for annual skin cancer screenings (18%). These shortcomings were more apparent in younger men (18-34), who were also significantly less likely to believe that they are at risk for skin cancer than men over 35 (31% vs. 42%), and are more likely to protect their skin for cosmetic reasons than they are for health reasons (32% vs. 20%).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7074231-american-academy-of-dermatology-spot-me-skin-cancer-awareness/
CVS Health, the nation’s largest pharmacy innovation company, today launched an in-store fundraising campaign at CVS Pharmacy locations nationwide to benefit the American Lung Association’s LUNG FORCE initiative which aims to make lung cancer, the leading cancer killer of women in the United States, a public health priority.
Now through June 11, customers can donate $1, $3 or more at the register at 7,900 CVS Pharmacy locations and online at www.cvs.com/lung (all proceeds will support the initiative). CVS Health is the national presenting sponsor of LUNG FORCE, which is focused on raising awareness about lung cancer in women, and increasing research funding to save lives.
To view the multimedia release go to:
http://www.multivu.com/players/English/7817251-cvs-health-lung-force-fundraiser/
